Swiss chemicals group Lonza said August 31 that it has signed a deal to sell a manufacturing facility in Singapore to a Roche-owned subsidiary for up to $360 million.
The purchase price of the cell culture biologic manufacturing facility was $290 million while an additional $70 million would be paid up if certain milestones were met, Lonza said.
Swiss pharmaceutical giant Roche said the facility will be merged with an existing facility run by its subsidiary Genentech Singapore.
Some 230 Lonza employees at the site would also join Genentech Singapore.
Copyright Agence France-Presse, 2009
